Share on

Middle East & Africa African Horse Sickness Treatment Market Research Report - Segmented By Clinical Form, Diagnosis & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Size, Share, Trends, Growth, Forecasts | 2023 to 2028

Published: March, 2023
ID: 5489
Pages: 145
Formats: report pdf report excel report power bi report ppt

Middle East & Africa African Horse Sickness Treatment Market Size & Growth (2023 to 2028)

The Size of the Middle East & Africa African Horse Sickness Treatment Market is valued at USD xx billion in 2023 and is estimated to reach USD xx billion by 2028, at a CAGR of xx.x% during the forecast period 2023 to 2028.

The two key drivers of expansion are increased awareness of HAT and the growing demand for better diagnostic tests. The primary factors that fuel the African Horse Sickness Vaccinations Market are an increased investment in R&D programs for developing numerous preventive vaccines and guidelines offered by regulatory organizations involved with species health for African horse sickness treatment.

The MEA African Horse Sickness Treatment Market will benefit from the development of technologically advanced healthcare infrastructure as well as ongoing research efforts in collaboration with international institutions and notable vendors for developing efficient vaccines.

The MEA is likely to benefit from one of the growing numbers of non-government and government programs aimed at raising knowledge about the value of vaccination in preventing life-threatening infections in animals.

Another factor to consider is that African horse sickness (AHS) is a highly contagious virus that can cause significant economic losses. AHS is characterized by fever, exhaustion, and respiratory problems such as trouble breathing. In some cases, neurological symptoms may emerge in horses infected with this virus.

Even though the horses are given the modified-live, multivalent vaccine, it does not promise that they will be protected from African Horse Sickness, simply that their chances of catching the disease will be lowered, a factor limiting market expansion. Furthermore, the development of the sector is limited by high immunization costs.

This research report on the Middle East & Africa African Horse Sickness Treatment Market has been segmented and sub-segmented into the following categories.

By Clinical Form:

  • Dikkop or Cardiac form
  • Dunkop or Pulmonary form
  • horse sickness fever
  • mixed form

By Diagnosis:

  • preventive treatment
    • vaccines and diagnostic tests
    • Serological Tests

By Country:

  • KSA
  • UAE
  • Israel
  • the rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the MEA African horse sickness treatment market holds a moderate position globally, expanding the regional significance. Businesses in the African Horse Sickness Treatment sector are increasingly more engaged with cutting-edge tactics such as targeted marketing and CSR activities.

The UAE African horse sickness treatment market is projected to witness a decent CAGR due to the notable trend observed across the board: these companies are now attempting to handle a particular business-related activity in a country with favorable regulations.

Authorities in developing countries such as the United Arab Emirates and Kuwait are putting policies in place to encourage international investors into their markets by lowering trade tariffs and taxes to create more jobs.

The Saudi Arabia African horse sickness treatment market is expected to grow faster owing to the various preventive vaccines in R & D activities that will benefit the market in this region. In addition, the availability of standard operating procedures and standards for treating African horse sickness has improved the need for African horse sickness treatment in all areas.

KEY MARKET PLAYERS

Key Market Companies dominating the MEA African Horse Sickness Treatment Market Profiled in the Report are Veterinary Serum and Vaccine Research Institute and Onderstepoort Biological Products SOC Ltd.,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample